Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Rampoldi A, Singh M, Wu Q, Duan M, Jha R, Maxwell JT, Bradner JM, Zhang X, Saraf A, Miller GW, Gibson G, Brown LA, Xu C. Toxicol Sci. 2019 May 1;169(1):280-292. (Emory University, USA)

Resolving the Reversed Rate Effect of Calcium Channel Blockers on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and the Impact on In Vitro Cardiac Safety Evaluation.
Zeng H, Wang J, Clouse H, Lagrutta A, Sannajust F. Toxicol Sci. 2019 Feb 1;167(2):573-580. (Merck & Co., Inc. PA, USA)

Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro.
Guo L, Eldridge S, Furniss M, Mussio J, Davis M. Toxicol Appl Pharmacol. 2018 Dec 1;360:88-98. (Leidos Biomedical Research, USA)

International Multisite Study of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G. Cell Rep. 2018 Sep 25;24(13):3582-3592. (FDA, MD, USA)

Deconvoluting Kinase Inhibitor Induced Cardiotoxicity.
Lamore SD, Ahlberg E, Boyer S, Lamb ML, Hortigon-Vinagre MP, Rodriguez V, Smith GL, Sagemark J, Carlsson L, Bates SM, Choy AL, Stålring J, Scott CW, Peters MF. Toxicol Sci. 2017 Jul 1;158(1):213-226. (AstraZeneca Pharmaceutical, USA)

Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry.
Lagrutta A, Regan CP, Zeng H, Imredy JP, Koeplinger K, Morissette P, Liu L, Wollenberg G, Brynczka C, Lebrón J, DeGeorge J, Sannajust F. Sci Rep. 2017 Mar 22;7:44820. (Merck & Co., Inc. PA, USA)

Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes.
Zhao L, Zhang B. Sci Rep. 2017 Mar 16;7:44735. (FDA, USA)

Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X, Guo L, Zeng H, White SL, Furniss M, Balasubramanian B, Lis E, Lagrutta A, Sannajust F, Zhao LL, Xi B, Wang X, Davis M, Abassi YA. J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:201-16. (Frederick National Laboratory for Cancer Research & Merck Research Laboratories, USA)

A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S. Toxicol Sci. 2015 Jan;143(1):147-55. (Quintiles Inc. USA)

An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
Scott CW, Zhang X, Abi-Gerges N, Lamore SD, Abassi YA, Peters MF. Toxicol Sci. 2014 Dec;142(2):331-8. (AstraZeneca Pharmaceuticals, UK)

Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.
Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL. Cardiovasc Toxicol. 2015 Apr;15(2):127-39. (AstraZeneca Pharmaceutical, USA)

Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
Guo L, Coyle L, Abrams RM, Kemper R, Chiao ET, Kolaja KL. Toxicol Sci. 2013 Dec;136(2):581-94. (Hoffmann-La Roche, USA)

Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.
Lamore SD, Kamendi HW, Scott CW, Dragan YP, Peters MF. Toxicol Sci. 2013 Oct;135(2):402-13. (AstraZeneca Pharmaceutical, USA)

Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ, Chiao E, Kolaja KL. Toxicol Sci. 2011 Sep;123(1):281-9. (Hoffmann-La Roche, USA)